LAAM maintenance vs methadone maintenance for heroin dependence

Area of Science:

• Pharmacology and Addiction Medicine
• Clinical Trial Analysis
• Public Health Interventions

Background:

• Levomethadyl acetate (LAAM) and methadone are full mu-opiate agonists used for heroin dependence treatment.
• LAAM offers a longer duration of action (dosing every 2-3 days) compared to daily methadone dosing.
• LAAM's international availability is limited, and it has been associated with cardiac arrhythmias and QT prolongation.

Purpose of the Study:

• To compare the efficacy and acceptability of LAAM maintenance therapy versus methadone maintenance therapy for heroin dependence.
• To evaluate key outcomes including treatment retention, heroin use reduction, and adverse events.

Main Methods:

• Systematic literature search of major databases (MEDLINE, PsycINFO, EMBASE, Cochrane) and NIDA monographs up to August 2000.
• Inclusion of randomized controlled trials, controlled clinical trials, and controlled prospective studies comparing LAAM and methadone.
• Independent data extraction by two reviewers on retention, heroin use, side-effects, and mortality, followed by meta-analysis.

Main Results:

• Eighteen studies met inclusion criteria; 15 were randomized controlled trials.
• Higher rates of medication cessation were observed with LAAM compared to methadone (RR 1.36, p=0.001).
• LAAM demonstrated greater effectiveness in reducing non-abstinence from heroin (RR 0.81, p=0.0003), with a trend towards increased mortality in the LAAM group (RR 2.28, p=0.2).

Conclusions:

• LAAM appears more effective than methadone in reducing illicit heroin use among individuals with heroin dependence.
• While more patients discontinued LAAM, many transitioned to methadone, obscuring the direct impact of cessation.
• No significant differences in overall safety were detected, but evidence on rare adverse events remains insufficient.